Malignant Peritoneal Mesothelioma Diagnosis
A physical examination and history are the first steps in diagnosing peritoneal mesothelial cancer. The earlier the diagnosis is made, the better. Diagnostic imaging tests may be ordered to identify the tumors and their location. These tests do not offer enough detail to identify the presence of cancer, however. A fine needle aspiration can be done to collect fluid and tissue from the abdomen and test them for abnormalities and signs of the disease.
There are two main types of malignant peritoneal mesoma, namely pleural and adenocarcinoma. Each type of mesothelioma has its own set of symptoms, which are important for diagnosis. Regardless of the type of peritoneal mesothelial cancer, it is important to determine the cause of the tumor to ensure that treatment is effective.
When diagnosed, patients should undergo an appropriate chemotherapy. Hyperthermic intraperitoneal chemotherapy is recommended. Depending on the location of the tumor, the cancer may spread throughout the abdominal cavity. In addition to the multidisciplinary approach, a biopsy may be necessary. If a tissue sample is positive for malignant pleural mesothelioma, a patient may require radiation therapy.
Symptoms may take anywhere from 10 to 50 years to manifest themselves. As a result, early symptoms will likely occur in the abdominal area and gastrointestinal system. However, the disease can also cause systemic symptoms, making a diagnosis more difficult. Often, the diagnosis of malignant peritoneal meso-tumus begins with imaging tests to rule out other cancers and diseases.
The next step in peritoneal mesothelium cancer is a biopsy. This procedure allows doctors to examine the tumor under a microscope to determine whether it is malignant or nonmalignant. This test allows a doctor to determine the exact location of the disease and confirm the diagnosis. Surgical debulking and intraperitoneal chemotherapy are often used in patients with malignant ovarian mesothelioma.
The disease is rare and is caused by a buildup of fatty deposits in the abdominal cavity. In addition to the abdomen, it can occur in the lungs, and even in the peritoneum. The cancers in the lungs are often found on the skin or in the visceral pleura. Both types of the disease can spread to other parts of the body.
While this type of cancer is rare, it does not occur frequently. It is the most common asbestos-related cancer, and accounts for less than 20 percent of all mesothelioma cases. The most effective treatment for peritoneal mesothelial mesothelioma is surgery combined with heated chemotherapy. While it is uncommon to develop this type of disease, the most effective treatments are highly targeted, and are aimed at preserving organ function.
For patients with malignant peritoneal mesoma, early diagnosis is essential. The earlier the disease is detected, the better the chance of finding a cure. If it is detected at an early stage, treatment may be more aggressive. Fortunately, treatments can increase the amount of time that a patient lives with no visible signs of cancer. Although aggressive treatments may be necessary, it is important to discuss the risks of various treatments with your medical care team. Choosing a care team with extensive experience is important.
A CT scan can help diagnose peritoneal mesothelial cancer. It may be difficult to get a clear diagnosis of the disease. A biopsy is required to confirm the diagnosis. A biopsy is the only way to determine if MPM is present. This test is the most effective way to distinguish malignant peritoneal mesotitis from other types of cancer.
The most common treatment for peritoneal mesothelial cancer is surgery. Oncologists may recommend a combination of chemotherapy and radiation. The most common option for treating the disease is chemotherapy, which can be given in combination with other treatments. Some patients may qualify for cutting-edge treatment and may have a cure. If this is not the case, a physician can also perform a biopsy in the affected area to confirm the diagnosis.
The prognosis of malignant peritoneal mesotage is determined by histologic type. The sarcomatoid and biphasic subtypes of MPM have a significantly worse outcome than the epithelioid subtype. The only subtypes with favorable prognoses include the Alexander ethelioid and sarcomatoid.